Product Images Alfuzosin Hydrochloride Extended Release

This text provides data on adverse events observed in a clinical trial comparing the placebo group to a group taking Alfuzosin HCI. The number of participants in each group is also provided. The adverse events reported include dizziness, upper respiratory tract infections, headache, and fatigue.*

This text provides a comparison of placebo and Alfuzosin HCI in the treatment of symptoms reported by 678 patients. The symptoms and their corresponding incidence rates are Dizziness (2.6% for placebo vs 65.7% for Alfuzosin HCI), Hypotension or postural (0 for placebo vs 0.4% for Alfuzosin HCI) and Syncope (0 for placebo vs 0.2% for Alfuzosin HCI).*

This is a graph showing the Mean Alfuzosin Plasma Concentration-Time profiles after a Single Administration of Alfuzosin Hydrochloride 10 mg tablets to 8 Healthy Middle-Aged Male Volunteers in Fed and Fasted States. The x-axis displays the plasma concentration in ng/mL, and the y-axis represents the time frame in hours. This graph could be used to study the pharmacokinetics of the medication in question.*

The text is presenting results of an experiment in three trials where participants were given Alfuzosin Hcl or Placebo for 12 weeks. The scores of the participants before and after the trials were recorded in terms of the total symptom score. The results show a significant decrease in the total symptom score in participants who were given Alfuzosin Hcl compared to Placebo. The p-values of all three trials were less than 0.01, indicating significant results.*

The text seems to be a part of a research paper or trial result analysis. It contains numerical data related to a medication called Altuzosin and its effects on the IPSS Total Symptom Score. The sample size for the study is 167 and the mean change in the score is mentioned in the text. Figure 2 shows the mean change from the baseline during the treatment period. Without proper context or additional information, it is not possible to provide more details about the study or its significance.*

This text describes a figure labeled as "Figure 3 - Mean Change from Baseline in IPSS Total Symptom Score: Trial 2." The information includes the number of days of treatment (28, 6, and 8) and the text "Mean Change." Without additional context or data, it is difficult to provide a more specific description or interpretation of the figure.*

The text describes a figure titled "Mean Change from Baseline in IPSS Total Symptom Score: Trial 3". The figure shows data for a treatment period of 2568 days, and the y-axis represents the mean change.*

The text is describing a figure showing the mean change from baseline in peak urine flow rate in Trial 1. It appears that there is a significant difference between the mean change before and after treatment as indicated by "p<0.001".*

This is a description of a medication, Alfuzosin HCI, which comes in 100 extended-release tablets with a strength of 10 mg each, packaged in a tight, light-resistant container to protect from light and moisture. The tablets are Rx only and dispensed with a patient information leaflet. The manufacturer is InvaGen Pharmaceuticals, Inc., a subsidiary of Cipla Ltd., and it is manufactured for Cipla USA, Inc. The medication must be kept out of reach of children and stored at 20-25°C (68-77°F). The package insert should be consulted for dosage information. The Lot number and expiration date are also provided.*